בית › מיאלומה מרובה › טנסי › Nashville
מחקרים קליניים עבור מיאלומה מרובה ב-Nashville, TN
32 מחקרים עבור מיאלומה מרובה מחפשים משתתפים באתרים ב-Nashville ובסביבתה (בטווח של כ-30 מייל). פתחו מחקר כדי לראות מי יכול להשתתף וכיצד ליצור קשר עם צוות המחקר.
טקסט רשמי של המחקר (באנגלית)
מגייסים משתתפים למחקר כאן? הציגו אותו בראש העמוד – $99 ל-30 ימים →
A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma (DURGA-4)
מגייסשלב 3
- Research Site, Nashville
A Long-term Study for Participants Previously Treated With Ciltacabtagene Autoleucel
מגייסשלב 4
- Sarah Cannon Research Institute, Nashville
A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma
מגייסשלב 3
- SCRI Oncology Partners, Nashville
- Vanderbilt University Medical Center, Nashville
A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma
מגייסשלב 3
- Tennessee Oncology, PLLC, Nashville
A Phase I, Open-label, Multicenter Study to Evaluate the Safety, Tolerability, Cellular Kinetics, Immunogenicity, Pharmacodynamics, and Preliminary Efficacy of AZD0120 in Participants With Multiple Myeloma (DURGA-2)
מגייסשלב 1
- Research Site, Nashville
A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma
מגייסשלב 3
- Henry-Joyce Cancer Clinic, Nashville
A Study of mRNA-2808 in Participants With Relapsed or Refractory Multiple Myeloma
מגייסשלב 1/2
- Sarah Cannon Research Institute, Nashville
TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer
מגייסשלב 2
- Tennessee Oncology - Nashville / Sarah Cannon Research Institute, Nashville
A Study to Assess A Change in Disease Activity and Adverse Events of Intravenous Etentamig and Daratumumab (Etentamig+D) Compared to Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Adult Participants With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant
מגייסשלב 2/3
- SCRI Oncology Partners /ID# 278353, Nashville
Study of Arlocabtagene Autoleucel (BMS-986393) a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma
מגייסשלב 2
- Tennessee Oncology, Nashville
- Vanderbilt University Medical Center, Nashville
A Study of Elranatamab Outpatient Administration in Patients With Relapsed/Refractory Multiple Myeloma
מגייסשלב 2
- SCRI Oncology Partners, Nashville
Study of SIM0500 Alone in Participants With Relapsed or Refractory Multiple Myeloma
מגייסשלב 1
- Tennessee Oncology, Nashville
A Modular, Phase I/II, Multicentre Study to Evaluate AZD4045, in Participants With Relapsed or Refractory Multiple Myeloma
מגייסשלב 1/2
- Research Site, Nashville
A Study to Evaluate the Efficacy and Safety of Belantamab Mafodotin in Combination With Standard of Care in Participants With Relapsed-Refractory Multiple Myeloma (RRMM)
מגייסשלב 2
- GSK Investigational Site, Nashville
MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)
מגייסשלב 3
- Ascension St. Thomas Hospital, Nashville
- Tennessee Oncology, PLLC - Investigational Drug Services, Nashville
- Tennessee Oncology, PLLC - Nashville Elliston Place Plaza Center for Blood Cancers, Nashville
- ועוד 2
Identifying Effective and Cost-Conscious Maintenance Daratumumab Dosing
מגייסשלב 2
- Vanderbilt University Medical Center, Nashville
A Study to Investigate the Safety and Efficacy of Belantamab for the Treatment of Multiple Myeloma When Used as Monotherapy and in Combination Treatments
מגייסשלב 1/2
- GSK Investigational Site, Nashville
A Study of an MMSET Inhibitor in Patients With Relapsed and Refractory Multiple Myeloma
מגייסשלב 1
- Tennessee Oncology, Nashville
A Trial to Learn if Linvoseltamab is Safe and Works in Adults With Relapsed or Refractory Systemic Light Chain Amyloidosis (AL Amyloidosis)
מגייסשלב 1/2
- SCRI Oncology Partners, Nashville
AZD0120 in Relapsed/Refractory Multiple Myeloma (DURGA-1)
מגייסשלב 1/2
- Research Site, Nashville
- Research Site, Nashville
Study of AZD0120 in Newly Diagnosed Multiple Myeloma Ineligible for ASCT
מגייסשלב 3
- Research Site, Nashville
- Research Site, Nashville
A Study to Evaluate the Efficacy of Cemsidomide + Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma
מגייסשלב 2
- Tennessee Oncology, Nashville
A Study to Evaluate the Safety, Effectiveness and Tolerable Dose of Arlocabtagene Autoleucel (BMS-986393) in Novel Combinations in Participants With Relapsed and/or Refractory Multiple Myeloma
מגייסשלב 1
- Tennessee Oncology, Nashville
A Study to Assess Adverse Events of Intravenously (IV) Infused Etentamig (ABBV-383) in Adult Participants With Relapsed or Refractory Multiple Myeloma
מגייסשלב 1
- Vanderbilt Ingram Cancer Center /ID# 252470, Nashville
Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation
מגייסשלב 3
- Vanderbilt-Ingram Cancer Center (VICC), Nashville
Frontline T-cell Engager vs Autologous Stem Cell Transplant (ASCT) and Measurable Residual Disease (MRD)-Guided Sequential Intensification thERapy in Multiple Myeloma
מגייסשלב 2
- SCRI Oncology Partners, Nashville
Outpatient Administration of Teclistamab or Talquetamab for Multiple Myeloma
מגייסשלב 2
- TriStar Bone Marrow Transplant, Nashville
- Vanderbilt- Ingram Cancer Center, Nashville
A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)
מגייסשלב 1/2
- TriStar Centennial Medical Center, Nashville
A Study to Assess BMS-986453 in Participants With Relapsed and/or Refractory Multiple Myeloma
מגייסשלב 1
- Local Institution - 0008, Nashville
- Tennessee Oncology, Nashville
cfDNA Assay Prospective Observational Validation for Early Cancer Detection and Minimal Residual Disease
מגייסמחקר תצפיתימתנדבים בריאים מוזמנים
- Vanderbilt-Ingram Cancer Center, Nashville
CRISPR-Edited Allogeneic Anti-BCMA CAR-T Cell Therapy in Patients With Relapsed/Refractory Multiple Myeloma
מגייסשלב 1
- Tennessee Oncology, Nashville
IDP-023 as a Single Agent and in Combination With Antibody Therapies in Patients With Advanced Hematologic Cancers
מגייסשלב 1/2
- SCRI Oncology Partners, Nashville
מחקרים עבור מיאלומה מרובה בערים אחרות
- New York City, NY60 מחקרים
- Boston, MA42 מחקרים
- Atlanta, GA42 מחקרים
- Houston, TX38 מחקרים
- Durham, NC37 מחקרים
- Denver, CO27 מחקרים
- Rochester, MN24 מחקרים
- St. Louis, MO24 מחקרים
- Columbus, OH24 מחקרים
- Baldwin Park, CA23 מחקרים
- Edison, NJ22 מחקרים
- Chicago, IL22 מחקרים
מחקרים אחרים ב-Nashville
- סרטן ריאות לא תא קטן97 מחקרים
- סרטן השד81 מחקרים
- סרטן גרורתי70 מחקרים
- סרטן המעי הגס והחלחולת69 מחקרים
- סרטן (כל הסוגים)65 מחקרים
- סרטן השחלות49 מחקרים
- סרטן הערמונית43 מחקרים
- סרטן הריאה40 מחקרים
- קרצינומה קשקשית של ראש וצוואר39 מחקרים
- סרטן הלבלב39 מחקרים
- סרטן אנדומטריאלי38 מחקרים
- מלנומה33 מחקרים
מקור: ClinicalTrials.gov, המידע אוחזר בתאריך 6 באוק׳ 2026. כל מחקר מגדיר את קריטריוני ההשתתפות שלו; צוות המחקר קובע מי יכול להשתתף.